Table 1.

Cohort characteristics

Demographics	Cohort (N=66)
Weight (kg), Median (Range)	20.1 (4.1-117.4)
Age (months), Median (Range)	78 (1–204)
Female	34 (52%)
Race
White	57 (86%)
Black	7 (11%)
Other/Unknown	2 (3%)
Primary Diagnosis Category
Neurologic	19 (29%)
Respiratory	16 (24%)
Sepsis	6 (9%)
Gastrointestinal/Transplant	6 (9%)
Other	19 (29%)
Mechanical Ventilation	61 (92%)
Neuromuscular Blockade	28 (42%)
Vasoactive Medication Infusion	25 (38%)
PICU Length of Stay (days), Median (Range)	8.4 (1.1–129)
Hospital Length of Stay (days), Median (Range)	15.5 (2.4–129.4)
Number of Samples per Patient, Median (Range)	4 (1–7)
Duration of Fentanyl Infusion (hours), Median (Range)	90.7 (11–254)
Number of Fentanyl Boluses per Patient, Median (Range)	25 (4–77)
Fentanyl Plasma Concentration (ng/mL), Median (Range)	2.29 (0.11–84.32)
Concomitant CYP3A Inducer/Inhibitor
Fosphenytoin	13 (20%)
Fosphenytoin + Phenobarbital	2 (3%)
Fosphenytoin + Phenobarbital	2 (3%)
Phenobarbital	2 (3%)
Fluconazole	5 (8%)
Genotype
CYP3A5, rs28365094, CT+CC	14(21%)